Is It Time to Buy This Growth Stock?
Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?
Why Cubist Pharmaceuticals Inc. Shares Soared in After-Hours Trading on Friday
Antibiotic drug developer Cubist Pharmaceuticals surges in after-hours trading following a report that a large pharmaceutical company may be interested in acquiring it for a handsome premium.
The Most Important FDA Decision We're Watching This Month
Three Motley Fool analysts tell investors which three FDA decisions they'll be watching closely in December.